Phase II Trial of PS-341 (Bortezomib, NSC-681239) Followed by the Addition of Gemcitabine at Progression in Recurrent or Metastatic Nasopharyngeal Carcinoma
Phase of Trial: Phase II
Latest Information Update: 24 Jan 2013
At a glance
- Drugs Bortezomib (Primary) ; Gemcitabine (Primary)
- Indications Nasopharyngeal cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 06 Mar 2008 Status changed from in progress to completed.
- 12 Oct 2006 New trial record.